Pacer Advisors’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Pacer Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$299K	Sell	8,811 -440	-5%	-$14.7K	﹤0.01%	1681
2026 Q1	$279K	Buy	9,251 +264	+3%	+$8.49K	﹤0.01%	1650
2025 Q4	$280K	Sell	8,987 -314	-3%	-$7.74K	﹤0.01%	1955
2025 Q3	$188K	Sell	9,301 -563	-6%	-$9.89K	﹤0.01%	1975
2025 Q2	$165K	Sell	9,864 -475	-5%	-$7.67K	﹤0.01%	1929
2025 Q1	$159K	Buy	10,339 +297	+3%	+$5.3K	﹤0.01%	1841
2024 Q4	$221K	Buy	10,042 +396	+4%	+$7.2K	﹤0.01%	1900
2024 Q3	$174K	Sell	9,646 -75	-0.8%	-$1.31K	﹤0.01%	1884
2024 Q2	$158K	Sell	9,721 -475	-5%	-$7.32K	﹤0.01%	1984
2024 Q1	$144K	Sell	10,196 -380	-4%	-$4.79K	﹤0.01%	2262
2023 Q4	$110K	Buy	10,576 +294	+3%	+$2.75K	﹤0.01%	2644
2023 Q3	$105K	Buy	10,282 +1,136	+12%	+$10.6K	﹤0.01%	2205
2023 Q2	$68.9K	Buy	9,146 +552	+6%	+$4.48K	﹤0.01%	2993
2023 Q1	$76.1K	Buy	8,594 +276	+3%	+$2.73K	﹤0.01%	1678
2022 Q4	$75.9K	Buy	+8,318	New	+$72.6K	﹤0.01%	2727
2022 Q1	–	Sell	-8,460	Closed	-$68K	–	2544
2021 Q4	$68K	Sell	8,460 -387	-4%	-$3.49K	﹤0.01%	2111
2021 Q3	$86K	Buy	8,847 +276	+3%	+$2.58K	﹤0.01%	1371
2021 Q2	$85K	Hold	8,571	–	–	﹤0.01%	1358
2021 Q1	$99K	Sell	8,571 -460	-5%	-$5.28K	﹤0.01%	1301
2020 Q4	$87K	Sell	9,031 -2,024	-18%	-$19.4K	﹤0.01%	1379
2020 Q3	$100K	Buy	+11,055	New	+$117K	﹤0.01%	1249
2020 Q1	–	Sell	-8,333	Closed	-$82K	–	1076
2019 Q4	$82K	Buy	8,333 +3,114	+60%	+$27.8K	﹤0.01%	1158
2019 Q3	$36K	Buy	5,219 +1,760	+51%	+$13.5K	﹤0.01%	1154
2019 Q2	$32K	Buy	+3,459	New	+$41.7K	﹤0.01%	1126
2018 Q2	–	Sell	-96,859	Closed	-$1.66M	–	1199
2018 Q1	$1.66M	Buy	96,859 +27,526	+40%	+$537K	0.09%	261
2017 Q4	$1.31M	Buy	69,333 +29,425	+74%	+$443K	0.09%	292
2017 Q3	$702K	Buy	39,908 +2,090	+6%	+$47K	0.06%	474
2017 Q2	$1.26M	Buy	+37,818	New	+$1.17M	0.12%	154
2013 Q4	$459K	Buy	+7,979	New	+$314K	0.11%	237

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Pacer Advisors's TEVA Position: Q2 2026 in Review

Pacer Advisors reduced its Teva Pharmaceutical Industries Limited (TEVA) stake by 4.8% in Q2 2026, selling an estimated $14.7K and leaving 8,811 shares worth $299K. The position accounts for ﹤0.01% of the portfolio, ranked #1681.

Pacer Advisors first reported a position in TEVA in Q4 2013 and has held it in 29 quarters since. The position peaked at $1.66M in Q1 2018. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Pacer Advisors held 8,811 shares of Teva Pharmaceutical Industries Limited worth $299K as of Q2 2026.
Pacer Advisors sold 440 Teva Pharmaceutical Industries Limited shares in Q2 2026, an estimated $14.7K.
Teva Pharmaceutical Industries Limited made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #1681 holding.
Pacer Advisors first reported a position in Teva Pharmaceutical Industries Limited in Q4 2013 and has held it in 29 quarters since.
Pacer Advisors's Teva Pharmaceutical Industries Limited position peaked at $1.66M in Q1 2018.
676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.